NATURAL ALTERNATIVES INTERNATIONAL INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NATURAL ALTERNATIVES INTERNATIONAL INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Jun 30, 2018 | $132.44M | Sep 19, 2018 |
| FY2018 | Jun 30, 2017 | $121.95M | Sep 19, 2018 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Jun 30, 2017 | $121.95M | Sep 18, 2017 |
| FY2017 | Jun 30, 2016 | $114.20M | Sep 18, 2017 |
| FY2016 | Jun 30, 2015 | $79.51M | Sep 19, 2016 |
| FY2015 | Jun 30, 2014 | $73.94M | Sep 18, 2015 |
| FY2014 | Jun 30, 2013 | $62.80M | Sep 25, 2014 |
| FY2013 | Jun 30, 2012 | $72.82M | Sep 19, 2013 |
| FY2012 | Jun 30, 2011 | $55.88M | Sep 21, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $9.29M | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | $6.87M | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | $18.16M | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | $30.51M | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | $30.44M | Sep 21, 2022 |
| FY2021 | Jun 30, 2020 | $18.87M | Sep 20, 2021 |
| FY2020 | Jun 30, 2019 | $23.58M | Sep 21, 2020 |
| FY2019 | Jun 30, 2018 | $26.32M | Sep 24, 2019 |
| FY2018 | Jun 30, 2017 | $26.20M | Sep 19, 2018 |
| FY2017 | Jun 30, 2016 | $25.26M | Sep 18, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($13.58M) | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | ($7.22M) | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | $2.52M | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | $10.71M | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | $10.77M | Sep 21, 2022 |
| FY2021 | Jun 30, 2020 | ($1.65M) | Sep 20, 2021 |
| FY2020 | Jun 30, 2019 | $6.54M | Sep 21, 2020 |
| FY2019 | Jun 30, 2018 | $5.05M | Sep 24, 2019 |
| FY2018 | Jun 30, 2017 | $7.24M | Sep 19, 2018 |
| FY2017 | Jun 30, 2016 | $9.55M | Sep 18, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($8.66M) | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | ($8.53M) | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | $4.71M | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | $13.68M | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | $13.67M | Sep 21, 2022 |
| FY2021 | Jun 30, 2020 | ($1.51M) | Sep 20, 2021 |
| FY2020 | Jun 30, 2019 | $5.96M | Sep 21, 2020 |
| FY2019 | Jun 30, 2018 | $9.53M | Sep 24, 2019 |
| FY2018 | Jun 30, 2017 | $9.70M | Sep 19, 2018 |
| FY2017 | Jun 30, 2016 | $12.26M | Sep 18, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.80M | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | $1.90M | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | $2.10M | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | $2.50M | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | $1.90M | Sep 21, 2022 |
| FY2021 | Jun 30, 2020 | $1.80M | Sep 20, 2021 |
| FY2020 | Jun 30, 2019 | $1.80M | Sep 21, 2020 |
| FY2019 | Jun 30, 2018 | $1.50M | Sep 24, 2019 |
| FY2018 | Jun 30, 2017 | $1.60M | Sep 19, 2018 |
| FY2017 | Jun 30, 2016 | $1.10M | Sep 18, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Jun 30, 2020 | $17.10M | Sep 21, 2020 |
| FY2020 | Jun 30, 2019 | $17.61M | Sep 21, 2020 |
| FY2019 | Jun 30, 2018 | $16.79M | Sep 24, 2019 |
| FY2018 | Jun 30, 2017 | $16.50M | Sep 19, 2018 |
| FY2017 | Jun 30, 2016 | $13.00M | Sep 18, 2017 |
| FY2016 | Jun 30, 2015 | $10.18M | Sep 19, 2016 |
| FY2015 | Jun 30, 2014 | $9.96M | Sep 18, 2015 |
| FY2014 | Jun 30, 2013 | $9.98M | Sep 25, 2014 |
| FY2013 | Jun 30, 2012 | $9.25M | Sep 19, 2013 |
| FY2012 | Jun 30, 2011 | $8.30M | Sep 21, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $5.93M | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | ($1.50M) | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | $7.02M | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | $11.87M | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | $20.81M | Sep 21, 2022 |
| FY2021 | Jun 30, 2020 | $3.69M | Sep 20, 2021 |
| FY2020 | Jun 30, 2019 | $6.56M | Sep 21, 2020 |
| FY2019 | Jun 30, 2018 | $1.83M | Sep 24, 2019 |
| FY2018 | Jun 30, 2017 | $14.14M | Sep 19, 2018 |
| FY2015 | Jun 30, 2015 | $2.68M | Sep 18, 2015 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $3.61M | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | $3.02M | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | $13.52M | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | $26.49M | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | $5.11M | Sep 21, 2022 |
| FY2021 | Jun 30, 2020 | $4.54M | Sep 20, 2021 |
| FY2020 | Jun 30, 2019 | $5.33M | Sep 21, 2020 |
| FY2019 | Jun 30, 2018 | $4.08M | Sep 24, 2019 |
| FY2018 | Jun 30, 2017 | $5.35M | Sep 19, 2018 |
| FY2017 | Jun 30, 2016 | $10.44M | Sep 18, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $151.94M | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | $162.34M | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | $134.15M | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | $146.00M | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | $120.28M | Sep 21, 2022 |
| FY2021 | Jun 30, 2020 | $120.20M | Sep 20, 2021 |
| FY2020 | Jul 1, 2019 | $114.26M | Sep 21, 2020 |
| FY2020 | Jun 30, 2019 | $93.49M | Sep 21, 2020 |
| FY2019 | Jun 30, 2018 | $85.21M | Sep 24, 2019 |
| FY2018 | Jun 30, 2017 | $72.61M | Sep 19, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $83.51M | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | $79.75M | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | $45.38M | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | $57.48M | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | $40.20M | Sep 21, 2022 |
| FY2021 | Jun 30, 2020 | $48.83M | Sep 20, 2021 |
| FY2020 | Jun 30, 2019 | $17.41M | Sep 21, 2020 |
| FY2019 | Jun 30, 2018 | $16.96M | Sep 24, 2019 |
| FY2018 | Jun 30, 2017 | $11.46M | Sep 19, 2018 |
| FY2017 | Jun 30, 2016 | $20.45M | Sep 18, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $68.43M | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | $82.60M | Sep 23, 2025 |
| FY2025 | Jun 30, 2023 | $88.77M | Sep 23, 2025 |
| FY2024 | Jun 30, 2022 | $88.52M | Sep 27, 2024 |
| FY2023 | Jun 30, 2021 | $80.08M | Sep 21, 2023 |
| FY2022 | Jun 30, 2020 | $71.38M | Sep 21, 2022 |
| FY2021 | Jun 30, 2019 | $76.08M | Sep 20, 2021 |
| FY2020 | Jun 30, 2018 | $68.25M | Sep 21, 2020 |
| FY2019 | Jun 30, 2017 | $61.15M | Sep 24, 2019 |
| FY2018 | Jun 30, 2016 | $53.73M | Sep 19, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $59.39M | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | $72.97M | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | $80.18M | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | $77.66M | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | $66.95M | Sep 21, 2022 |
| FY2021 | Jun 30, 2020 | $56.18M | Sep 20, 2021 |
| FY2020 | Jul 1, 2019 | $57.80M | Sep 21, 2020 |
| FY2020 | Jun 30, 2019 | $57.38M | Sep 21, 2020 |
| FY2019 | Jun 30, 2018 | $50.84M | Sep 24, 2019 |
| FY2018 | Jun 30, 2017 | $45.79M | Sep 19, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $12.33M | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | $11.98M | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | $13.60M | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | $21.83M | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | $32.13M | Sep 21, 2022 |
| FY2021 | Jun 30, 2020 | $30.48M | Sep 20, 2021 |
| FY2020 | Jun 30, 2019 | $25.04M | Sep 21, 2020 |
| FY2019 | Jun 30, 2018 | $23.61M | Sep 24, 2019 |
| FY2019 | Jun 30, 2017 | $27.84M | Sep 24, 2019 |
| FY2018 | Jun 30, 2016 | $19.75M | Sep 19, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Jun 30, 2019 | $0 | Sep 24, 2019 |
| FY2018 | Jun 30, 2018 | $0 | Sep 19, 2018 |
| FY2017 | Jun 30, 2017 | $0 | Sep 18, 2017 |
| FY2016 | Jun 30, 2016 | $0 | Sep 19, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | (2) | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | (1) | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | 1 | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | 1 | Sep 21, 2022 |
| FY2021 | Jun 30, 2020 | 0 | Sep 20, 2021 |
| FY2020 | Jun 30, 2019 | 0 | Sep 21, 2020 |
| FY2019 | Jun 30, 2018 | 0 | Sep 24, 2019 |
| FY2018 | Jun 30, 2017 | 1 | Sep 19, 2018 |
| FY2017 | Jun 30, 2016 | 1 | Sep 18, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | (2) | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | (1) | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | 1 | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | 1 | Sep 21, 2022 |
| FY2021 | Jun 30, 2020 | 0 | Sep 20, 2021 |
| FY2020 | Jun 30, 2019 | 0 | Sep 21, 2020 |
| FY2019 | Jun 30, 2018 | 0 | Sep 24, 2019 |
| FY2018 | Jun 30, 2017 | 1 | Sep 19, 2018 |
| FY2017 | Jun 30, 2016 | 1 | Sep 18, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 6.18M | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | 6.20M | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | 6.07M | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | 6.13M | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | 6.44M | Sep 21, 2022 |
| FY2021 | Jun 30, 2020 | 6.75M | Sep 20, 2021 |
| FY2020 | Jun 30, 2019 | 7.23M | Sep 21, 2020 |
| FY2019 | Jun 30, 2018 | 7.56M | Sep 24, 2019 |
| FY2018 | Jun 30, 2017 | 6.94M | Sep 19, 2018 |
| FY2017 | Jun 30, 2016 | 6.87M | Sep 18, 2017 |